Portrazza
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Portrazza, covering 2015-11-24 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor [Phase 1]